Array BioPharma Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
|Company Name:||Array BioPharma Inc|
|Stock Symbol :||NASDAQ: ARRY|
|Class Period Start:||12/16/2015|
|Class Period End:||03/17/2017|
|Lead Plaintiff motion:||01/22/2018|
|Type of Case:||Securities Class Action|
|Court:||U.S. District Court for the District of Colorado|
Thieler Law Corp advises investors with losses exceeding $100,000 of the January 22, 2018 lead plaintiff deadline in a class action lawsuit filed against Array BioPharma Inc (NASDAQ: ARRY) (“Array” or “the Company”). The suit is pending in the U.S. District Court for the District of Colorado and investors, who purchased Array BioPharma Inc securities between December 16, 2015 and March 17, 2017, have until January 22, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.
If you purchased Array BioPharma Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing firstname.lastname@example.org . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.
The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Array’s NEMO study failed to show sufficient clinical benefit of the binimetinib NDA in use for patients with NRAS-mutant melanoma; it was aware that this lack of supporting data would not be sufficient to receive FDA approval of binimetinib in use for patients with NRAS-mutual melanoma; and as a result of the foregoing, Array’s public statements were materially false and misleading at all relevant times.
On March 19, 2017, the Company issued a press release revealing the withdrawal of the New Drug Application ("NDA") for the Company's cancer drug binimetinib, stating that "based on feedback from the [U.S. Food and Drug Administration], Array concluded that the clinical benefit demonstrated in [a recent Phase 3 clinical trial] would not be found sufficient to support approval" of the NDA.
Following this news, NASDAQ: ARRY dropped $1.43, or 13.5%, over two trading days, to close at $9.13 on March 21, 2017.
If you were negatively impacted by your investment in Array BioPharma Inc securities between December 16, 2015 and March 17, 2017 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.
Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.
Thieler Law Corp
2534 State Street - Suite 406,
San Diego, CA 92101
telephone at +1 (619) 377 - 4324
visit our website http://www.thielerlaw.com/
Facsimile: +1 (619) 785 – 3185